U.S. Markets closed

CASI Pharmaceuticals, Inc. (CASI)

NasdaqCM - NasdaqCM Real Time Price. Currency in USD
Add to watchlist
1.6400-0.0500 (-2.96%)
At close: 4:00PM EDT

1.6700 +0.03 (1.83%)
After hours: 7:58PM EDT

Full screen
Trade prices are not sourced from all markets
Gain actionable insight from technical analysis on financial instruments, to help optimize your trading strategies
Chart Events
Neutralpattern detected
Previous Close1.6900
Open1.7000
Bid1.6500 x 1100
Ask1.6600 x 3100
Day's Range1.6400 - 1.7200
52 Week Range1.4600 - 3.9000
Volume927,830
Avg. Volume1,161,381
Market Cap229.267M
Beta (5Y Monthly)0.22
PE Ratio (TTM)N/A
EPS (TTM)-0.4370
Earnings DateMay 10, 2021 - May 14, 2021
Forward Dividend & YieldN/A (N/A)
Ex-Dividend DateN/A
1y Target Est4.25
  • CASI Pharmaceuticals Announces Full Year 2020 Financial Results
    PR Newswire

    CASI Pharmaceuticals Announces Full Year 2020 Financial Results

    CASI Pharmaceuticals, Inc. (Nasdaq: CASI), a U.S. biopharmaceutical company focused on developing and commercializing innovative therapeutics and pharmaceutical products, today reported financial results for the year ended December 31, 2020 and provided an update on key highlights for 2021.

  • Why CASI Pharmaceuticals Is Crashing Today
    Motley Fool

    Why CASI Pharmaceuticals Is Crashing Today

    CASI Pharmaceuticals (NASDAQ: CASI) was down by roughly 15% in late trading on Wednesday, against the more or less flat performance of the S&P 500 index. CASI announced Wednesday morning that it is issuing just under 15.9 million shares of its common stock at a price of $2.05 per share. CASI said it will utilize the monies "for working capital and general corporate purposes."

  • CASI Pharmaceuticals Announces Pricing Of $32,500,000 Public Offering Of Common Stock
    PR Newswire

    CASI Pharmaceuticals Announces Pricing Of $32,500,000 Public Offering Of Common Stock

    CASI Pharmaceuticals, Inc. (Nasdaq: CASI), a U.S. biopharmaceutical company focused on developing and commercializing innovative therapeutics and pharmaceutical products, today announced the pricing of an underwritten public offering of 15,853,658 shares of its common stock at a price to the public of $2.05 per share. CASI has granted the underwriters an option to purchase up to an additional 2,378,048 shares of common stock, which terminates on the earlier of 30 days and the day before CASI files to the U.S. Securities and Exchange Commission ("SEC") its Annual Report on Form 10-K for the fiscal year ended December 31, 2020. The offering is expected to close on or about March 26, 2021, subject to satisfaction of customary closing conditions. The gross proceeds to CASI from the offering, excluding any exercise by the underwriters of their option to purchase additional shares, are expected to be approximately $32.5 million, before deducting underwriting discounts and commissions and other offering expenses payable by CASI.